Oral diazoxide versus placebo for severe or recurrent neonatal hypoglycaemia: Neonatal Glucose Care Optimisation (NeoGluCO) study – a randomised controlled trial
Introduction Infants with severe or recurrent transitional hypoglycaemia continue to have high rates of adverse neurological outcomes and new treatment approaches are needed that target the underlying pathophysiology. Diazoxide is one such treatment that acts on the pancreatic β-cell in a dose-depen...
Main Authors: | Jane E Harding, Wayne S Cutfield, J Geoffrey Chase, Jane M Alsweiler, Jenny Rogers, Julena Ardern, Greg D Gamble, Sara M Hanning, Michael P Meyer, Don Laing, Eamon Walsh, Christopher JD McKinlay |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-08-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/8/e059452.full |
Similar Items
-
Development and clinical application of a stability-indicating chromatography technique for the quantification of diazoxide
by: Trusha J. Purohit, et al.
Published: (2023-09-01) -
Continuous glucose monitoring in neonates: a review
by: Christopher J.D. McKinlay, et al.
Published: (2017-10-01) -
Prophylactic Oral Dextrose Gel for Newborn Babies at Risk of Neonatal Hypoglycaemia: A Randomised Controlled Dose-Finding Trial (the Pre-hPOD Study).
by: Joanne Elizabeth Hegarty, et al.
Published: (2016-10-01) -
Cost burden and net monetary benefit loss of neonatal hypoglycaemia
by: Matthew J. Glasgow, et al.
Published: (2021-02-01) -
Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
by: Ellada Sotiridou, et al.
Published: (2021-01-01)